Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública Sergio Arouca, Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.
Rev Soc Bras Med Trop. 2024 Jul 29;57:e00202. doi: 10.1590/0037-8682-0629-2023. eCollection 2024.
This study aimed to reinforce the importance of the epidemiological surveillance of multidrug-resistant tuberculosis (MDR-TB) in Rio de Janeiro State (RJ). Here, we reviewed seven articles we published between 2018 and 2022. This study had two phases. The quantitative phase where frequency was used to describe patient characteristics and regressions were used to evaluate the relationship between treatment outcomes and covariates. The qualitative phase where content analysis of the narratives was performed. Secondary (electronic systems) and primary (semi-structured interviews) data were used. We analyzed 2,269 MDR-TB, 58.1% MDR-TB, and 18.6% extensively drug-resistant TB (XDR-TB) cases, of which 44.3% exhibited unfavorable outcomes. Among the 140 patients with XDR-TB, 29.3% had not undergone prior treatment for MDR-TB. The primary resistance rate in MDR-TB cases was 14.7%, revealing significant demographic and clinical disparities, particularly among women, Caucasians, and those with higher education levels. The number of cases increased from 7.69% in 2000 to 38.42% in 2018, showing an increasing trend (AAPC = 9.4; 95% CI 1.4-18.0, p < 0.001), with 25.4% underreporting. A qualitative study confirmed a high proportion of primary resistance (64.5%) and delayed diagnosis of MDR-TB. In RJ, the diagnostic and therapeutic cascade of MDR-TB must be improved using molecular tests to achieve an early diagnosis of resistance and immediate initiation of appropriate treatment, promote social protection for MDR/XDR-TB patients and their families, enhance TB contact tracing, establish and monitor hospital surveillance centers integrated with Primary Care, and unify various information systems through interoperability for better integration.
本研究旨在强调里约热内卢州(里约州)开展耐多药结核病(MDR-TB)的流行病学监测的重要性。在这里,我们回顾了我们在 2018 年至 2022 年期间发表的七篇文章。本研究分为两个阶段。定量阶段使用频率来描述患者特征,并使用回归来评估治疗结果与协变量之间的关系。定性阶段则对叙述进行内容分析。使用了二级(电子系统)和一级(半结构化访谈)数据。我们分析了 2269 例 MDR-TB、58.1% MDR-TB 和 18.6%广泛耐药结核病(XDR-TB)病例,其中 44.3%的结果不理想。在 140 例 XDR-TB 患者中,29.3%未接受过 MDR-TB 的前期治疗。MDR-TB 病例的原发性耐药率为 14.7%,显示出显著的人口统计学和临床差异,尤其是在女性、白种人和受教育程度较高的人群中。MDR-TB 病例的数量从 2000 年的 7.69%增加到 2018 年的 38.42%,呈上升趋势(AAPC=9.4;95%CI 1.4-18.0,p<0.001),漏报率为 25.4%。一项定性研究证实,原发性耐药率很高(64.5%),MDR-TB 的诊断也存在延迟。在里约州,必须使用分子检测来改进 MDR-TB 的诊断和治疗级联,以实现对耐药性的早期诊断并立即开始适当的治疗,为 MDR/XDR-TB 患者及其家属提供社会保护,加强结核接触者追踪,建立并监测与初级保健相结合的医院监测中心,并通过互操作性统一各种信息系统,以实现更好的整合。